Lexicon Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Lexicon Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Lexicon Pharmaceuticals Inc Strategy Report
- Understand Lexicon Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company engaged in the development of sotagliflozin in type 1 diabetes, which was the subject of a separate NDA, in which NDA is in positive results of the third phase clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin for heart failure and type 1 diabetes. Its clinical and preclinical development programs, LX9211, are meant for the treatment of diabetes and neuropathic pain, respectively. It has business collaborations with several pharmaceutical and biotechnology companies. The company operates an office in New Jersey and has a laboratory in Texas. Lexicon is headquartered at The Woodlands, Texas, the US.
Headquarters
United States of America
Address
8800 Technology Forest Place, 8800 Technology Forest Place, The Woodlands, Texas, 77381
Website
www.lexpharma.com
Telephone
1 281 8633000
No of Employees
285
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LXRX (NASD)
Revenue (2022)
$1.2M
766.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-73.7%
(2022 vs 2021)
Market Cap*
$417.4M
Net Profit Margin (2022)
XYZ
79.9%
(2022 vs 2021)
* As of and is in US$
Lexicon Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Zynquista |
| Sotagliflozin: | |
| Type 1 Diabetes | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In May, the company announced that the U.S. Food and Drug Administration (FDA) approved INPEFA, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure. |
| 2022 | Regulatory Approval | In July, the company announced that the U.S. Food and Drug Administration accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor. |
| 2022 | Contracts/Agreements | In June, Lexicon IHM signed memorandum of understanding with Sarovar Hotels and Resorts to mentor and guide young hospitality aspirants. |
Competitor Comparison
| Key Parameters | Lexicon Pharmaceuticals Inc | Acorda Therapeutics Inc | RepliCel Life Sciences Inc | Geron Corp |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Canada | United States of America |
| City | The Woodlands | Pearl River | Vancouver | Foster City |
| State/Province | Texas | New York | British Columbia | California |
| No. of Employees | 285 | 102 | 1 | 141 |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Raymond Debbane | Chairman | Executive Board | 2012 | - |
| Lonnel Coats | Director; Chief Executive Officer | Executive Board | 2014 | 58 |
| Jeffrey L. Wade | Chief Financial Officer; President | Senior Management | 2021 | 58 |
| Craig Granowitz, M.D., Ph.D. | Chief Medical Officer; Senior Vice President | Senior Management | 2021 | 58 |
| Tom Garner | Chief Commercial Officer; Senior Vice President | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward